- Home
- ETON vs ANVS Comparison
ETON vs ANVS Comparison
Compare ETON & ANVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ETON
- ANVS
- Stock Information
- Founded
- ETON 2017
- ANVS 2008
- Country
- ETON United States
- ANVS United States
- Employees
- ETON N/A
- ANVS N/A
- Industry
- ETON Biotechnology: Pharmaceutical Preparations
- ANVS Biotechnology: Pharmaceutical Preparations
- Sector
- ETON Health Care
- ANVS Health Care
- Exchange
- ETON Nasdaq
- ANVS Nasdaq
- Market Cap
- ETON 199.5M
- ANVS 110.4M
- IPO Year
- ETON 2018
- ANVS 2020
- Fundamental
- Price
- ETON $8.82
- ANVS $9.64
- Analyst Decision
- ETON Strong Buy
- ANVS Strong Buy
- Analyst Count
- ETON 3
- ANVS 6
- Target Price
- ETON $12.00
- ANVS $29.67
- AVG Volume (30 Days)
- ETON 214.1K
- ANVS 341.4K
- Earning Date
- ETON 11-11-2024
- ANVS 11-06-2024
- Dividend Yield
- ETON N/A
- ANVS N/A
- EPS Growth
- ETON N/A
- ANVS N/A
- EPS
- ETON N/A
- ANVS N/A
- Revenue
- ETON $31,381,000.00
- ANVS N/A
- Revenue This Year
- ETON $19.61
- ANVS N/A
- Revenue Next Year
- ETON $35.39
- ANVS N/A
- P/E Ratio
- ETON N/A
- ANVS N/A
- Revenue Growth
- ETON 8.14
- ANVS N/A
- 52 Week Low
- ETON $3.03
- ANVS $4.53
- 52 Week High
- ETON $8.66
- ANVS $22.49
- Technical
- Relative Strength Index (RSI)
- ETON 76.07
- ANVS 58.70
- Support Level
- ETON $7.58
- ANVS $9.00
- Resistance Level
- ETON $8.66
- ANVS $10.54
- Average True Range (ATR)
- ETON 0.42
- ANVS 0.81
- MACD
- ETON -0.07
- ANVS 0.12
- Stochastic Oscillator
- ETON 91.49
- ANVS 74.57
About ETON Eton Pharmaceuticals Inc.
Eton Pharmaceuticals Inc is a United States based specialty pharmaceutical company. The company is engaged in developing and commercializing pharmaceutical products to fulfill an unmet patient need. It has four commercial rare disease products, Alkindi Sprinkle for the treatment of adrenocortical insufficiency; Carglumic Acid for the treatment of hyperammonemia, Betaine Anhydrous for the treatment of homocystinuria; and Nitisinone for the treatment of hereditary tyrosinemia type 1 (HT-1). The Company has three additional product candidates in late-stage development: ET-400, ET-600, and ZENEO hydrocortisone autoinjector.
About ANVS Annovis Bio Inc.
Annovis Bio Inc is a clinical-stage pharmaceutical company focused on developing and commercializing drugs for the treatment of Parkinson's and Alzheimer's diseases and other neurodegenerative diseases. The pipeline products of the company consists of: Buntanetap for chronic neurodegeneration - including AD and PD; ANVS405 for acute neurodegeneration; and ANVS301 for advanced AD.